Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
NCT ID: NCT00469755
Last Updated: 2022-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
302 participants
INTERVENTIONAL
2006-02-28
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
NCT04797793
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
NCT01095640
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
NCT00829049
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
NCT00660985
Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris
NCT00145106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Differin® Gel, 0.1% for 12 weeks
Adapalene Gel, 0.1%
Apply once daily in the evening for 12 weeks
2
Tazorac® Cream, 0.1% for 12 weeks
Tazarotene Cream, 0.1%
Apply once daily in the evening for 12 weeks
3
Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adapalene Gel, 0.1%
Apply once daily in the evening for 12 weeks
Tazarotene Cream, 0.1%
Apply once daily in the evening for 12 weeks
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open comedones and closed comedones) on the face, excluding the nose
Exclusion Criteria
12 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Galderma Laboratories, L.P.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald W Gottschalk, MD
Role: STUDY_DIRECTOR
Galderma R&D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Therapeutics Clinical Research
San Diego, California, United States
Henry Ford Medical Center-Dept. of Dermatology
Detroit, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
State University of New York Downstate Medical Center-Dept. of Dermatology
Brooklyn, New York, United States
Dermatology Research Associates
Cincinnati, Ohio, United States
Phoebe Rich, MD & Associates
Portland, Oregon, United States
Milton S. Hershey Medical Center Center-Div. of Dermatology
Hershey, Pennsylvania, United States
DermResearch, Inc.
Austin, Texas, United States
J & S Studies, Inc.
Bryan, Texas, United States
Stephens & Associates
Carrollton, Texas, United States
Dermatology Research Center
Salt Lake City, Utah, United States
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US10026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.